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1. Introduction
The term “nanoscale” refers to particle size range from ~ 1 to 100 nm [1], but for the purpose
of drug delivery, nanoparticles in the range of 50 – 500 nm are acceptable depending on the
route of administration. The method by which a drug is delivered can have a significant effect
on its efficacy. Some drugs have an optimum concentration range within which maximum
benefit is derived and concentrations above or below this range can be toxic or produce no
therapeutic benefit. The slow progress in the efficacy of the treatment of several diseases has
suggested a growing need for a multidisciplinary approach to the delivery of therapeutics to
target tissues [2]. Transdermal drug delivery systems (TDDS) or patches are controlled-release
devices that contain the drug either for localized treatment of tissues underlying the skin or
for systemic therapy after topical application to the skin surface [3]. TDDS are available for a
number of drugs, although the formulation matrices of these delivery systems differ. They
differ from conventional topical formulations in the following ways:
• they have an impermeable occlusive backing film that prevents intensive water loss from
the skin beneath the patch;
• the formulation matrix of the patch maintains the drug concentration gradient within the
device after application so that drug delivery to the interface between the patch and the skin
is sustained; and
• TDDS are kept in place on the skin surface by an adhesive layer ensuring drug contact with
the skin and continued drug delivery [4].
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Topical or transdermal drug delivery is challenging because the skin acts as a natural and
protective barrier. TDDS were introduced into the US market in the late 1970s [5], but trans‐
dermal delivery of drugs had been used for a very long time. There have been previous reports
about the use of mustard plasters to alleviate chest congestion and belladonna plasters as
analgesics. The mustard plasters were homemade as well as available commercially where
mustard seeds were ground and mixed with water to form a paste, which was in turn used to
form a dispersion type of delivery system. Several methods have been examined to increase
the permeation of therapeutic molecules into and through the skin and one such approach is
use of nanoparticulate delivery system.
The skin has been an important route for drug delivery when topical, regional, or systemic
effects are desired. Nevertheless, skin constitutes an excellent barrier and presents difficulties
for the transdermal delivery of therapeutic agents, since few drugs possess the characteristics
required to permeate across the stratum corneum in sufficient quantities to reach a therapeutic
concentration in the blood [6]. In order to enhance drug transdermal absorption, different
methodologies have been investigated, developed, and patented. Improvement in physical
permeation-enhancement technologies has led to renewed interest in transdermal drug
delivery. Some of these novel advanced transdermal permeation-enhancement technologies
include iontophoresis, electroporation, ultrasound, microneedles to open up the skin, and
more recently the use of transdermal nanocarriers.
2. The human skin
The potential of using the intact skin as the port of drug administration to the human body
has been recognized for several decades. However, the skin is a very difficult barrier to the
ingress of materials allowing only small quantities of a drug to penetrate over a period of time.
In order to design a drug delivery system, one must first understand the skin anatomy and its
implication of drug-of choice and method of delivery.
The human skin is the largest organ in our body with surface area of 1.8-2.0 m2. It is composed
of three main layers; the epidermis, dermis and hypodermis (subcutaneous layer) (Fig. 1). The
skin is a well energized organ that protects the organism against environmental factors and
regulates heat and water loss from the body.
3. Routes of drug penetration through the skin
The permeation of drugs through the skin involves the diffusion through the intact epidermis
through the skin appendages (hair follicles and sweat glands). These skin appendages form
shunt pathways through the intact epidermis, occupying only 0.1% of the total human skin. It
is known that drug permeation through the skin is usually limited by the stratum corneum
(Fig. 2). Three main penetration routes are recognized (Fig. 3).
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(http://www.spring8.or.jp/en/news_publications/press_release/2011/110406/. Downloaded April 26, 2014).
Figure 2. The stratum corneum
3.1. The intercellular lipid route
Interlamellar regions in the stratum corneum, including linker regions, contain less ordered
lipids and more flexible hydrophobic chains. This is the reason for the nonplanar spaces
between crystalline lipid lamellae and their adjacent cells’ outer membrane. Fluid lipids in skin
barrier are crucially important for transepidermal diffusion of the lipidic and amphiphilic
molecules, occupying those spaces for the insertion and migration through intercellular lipid
Figure 1. Structure of the skin (http://www.naturalrussia.com/natural/skin/structure.html. Downloaded on April 26,
2014)
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layers of such molecules [7]. The hydrophilic molecules diffuse predominantly “laterally”
along surfaces of the less abundant water-filled interlamellar spaces or through such volumes;
polar molecules can also use the free space between a lamella and a corneocyte outer membrane
to the same end.
3.2. The transcellular route
Intracellular macromolecular matrix within the stratum corneum abounds in keratin, which
does not contribute directly to the skin diffusive barrier but supports mechanical stability and
thus intactness of the stratum corneum. Transcellular diffusion is practically unimportant for
transdermal drug transport [8]. The narrow aqueous transepidermal pathways have been
observed using confocal laser scanning microscopy. Here, regions of poor cellular and
intercellular lipid packing coincide with wrinkles on skin surface and are simultaneously the
sites of lowest skin resistance to the transport of hydrophilic entities. This lowest-resistance
pathway leads between clusters of corneocytes at the locations where such cellular groups
show no lateral overlap. The contribution to transdermal drug transport can increase with
pathway widening or multiplication, e.g., that which is caused by exposing the stratum
corneum to a strong electrical (electroporation/iontophoresis), mechanical (sonoporation/
sonophoresis), or thermal stimulus, or suitable skin penetrants.
3.3. Follicular penetration
Recently, follicular penetration has become a major focus of interest due to the fact that drug
targeting to the hair follicle is of great interest in the treatment of skin diseases. However,
follicular orifices occupy only 0.1% of the total skin surface area. For this reason, it was assumed
to be a nonimportant route for drug penetration. But a variety of studies have shown that hair
follicles could be an interesting option for drug penetration through the skin [6]. Such follicular
pathways have also been proposed for topical administration of polystyrene nanoparticles.
They were investigated in porcine skin (ex vivo) and human skin (in vivo). Surface images
revealed that polystyrene nanoparticles accumulated preferentially in the follicular openings.
This distribution was increased in a time-dependent manner, and the follicular localization
was favored by the smaller particle size. The study also confirmed similarity in the penetration
between both membranes (porcine and human skin). In other investigations, the influence of
microparticle size in skin penetration has been shown by differential stripping. Nanoparticles
can act as efficient drug carriers through the follicle or can be utilized as follicle blockers to
stop the penetration of topically applied substances.
4. Main factors for nano-based delivery system
4.1. Particle size, size distribution and zeta potential
Particle size and shape affect drug release, physical stability and cellular uptake of the
nanoparticulate materials. The yield and size distribution of each system are affected by certain
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in-process operations and conditions such as stirring rate, temperature, type and amount of
dispersing agent as well as the viscosity of the organic and aqueous phases [9,10]. Zeta potential
of a dispersion is necessary for dispersion stability [11].
4.2. Surface properties
The attachment of nanoparticles to cell membrane is affected by the surface charge of the
particles. Variation of the particle surface charge could potentially control binding to the tissue
and direct nanoparticles to cellular compartments both in vitro and in vivo. Cellular surfaces
are dominated by negatively charged sulphated proteoglycans molecules that play pivotal
roles in cellular proliferation, migration and motility [12]. Cell surface proteoglyans consist of
a core protein anchored to the membrane and linked to one or more glycosaminoglycan side
chains (heparan, dermatan, keratan or chondrotine sulfates) to produce a structure that extends
away from the cell surface.
Figure 3. Structure of the skin showing routes of penetration: (1) across the intact horny layer, (2) through the hair
follicles with the associated sebaceaous glands, or (3) via the sweat glands (http://www.skin-care-
forum.basf.com/en/author-articles/strategies-for-skin-penetration-enhancement/2004/08/12?
id=5b9a9164-6148-4d66-bd84-6df76bd6d111&mode=Detail. Downloaded April 26, 2014).
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Nanoparticles show a high affinity for cellular membrane mainly due to electrostatic interac‐
tions [12]. It is known that cell membranes have large negatively charged domains, which
should repel negatively charged nanoparticles. The high cellular uptake of negatively charged
nanoparticles is related first to the non-specific process of nanoparticles adsorption on the cell
membrane and second to formation of nanoparticle clusters [13]. The adsorption of the
negatively charged particles at the positively charged sites via electrostatic interaction can lead
to localized neutralization and a subsequent bending of the membrane favouring in turn
endocytosis for cellular uptake [14]. Thus the formulation of nanoparticles with different
surface properties can influence their cellular uptake and intracellular distribution and it is
possible to localize the nanoparticles to specific intracellular targets (lysosomes, mitochondria,
cytoplasm, etc) by modifying their surface charge [15].
There are some investigations that showed the effect of surface charge, for example polymer
charge density of dendrimers was found to significantly impact membrane permeability. The
most densely charged polymer facilitates the transport of dye molecule across the membrane
[16]. Other investigation showed that lipid coating of ionically charged nanoparticles was able
to increase endothelial cell layer crossing 3 or 4 fold compared with uncoated particles, whereas
nanoparticles coating of neutral particles did not significantly alter their permeation charac‐
teristics across the endothelial cell monolayer [13]. Transdermal drug administration systems
have been limited to certain drugs of a range of molecular weight and lipophilicity, and of
certain charge preference. For instance, cationic compounds have a positive effect on skin
permeation, since the skin carries a negative surface charge due to phosphatidylcholine [17]
and carbohydrates found in mammalian cells contain negatively charged groups. Therefore,
nanoparticles with predominant positive charge would promote transdermal permeation.
5. Dermatopharmacokinetics
Dermatopharmacokinetics describe the pharmacokinetics of topically applied drugs in the
stratum corneum with pharmacodynamic effects. The smart techniques (tape stripping and
microdialysis) use in dermatopharmacokinetic methodology assesses the cutaneous drug
concentration at the site of application. Various studies have shown dermatopharmacokinetics
to be a reliable and reproducible method for determining bioequivalence, and have indicated
that it is applicable for all topical dermatological drug products. Dermatopharmacokinetics
refer to the determination of stratum corneum concentration-time curves for topical actives.
This is analogous to plasma/urine concentration-time curves for systemically or orally
administered drugs, and the concept is clearly adaptable to microdialysis, where drug is
determined in the skin compartment in which the microdialysis fibre is positioned (Fig. 4).
Although, this procedure is invasive, it is a method of great potential offering information of
high value and relevance. There could be sampling in a compartment within the skin. It is a
technically demanding procedure, however, requiring experimental dexterity of high order.
The potential for use on diseased skin is a unique and considerable advantage over other
techniques, but real challenges remain with respect to reproducibility, sensitivity, applicable
drugs, etc.
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Stratum corneum tape-stripping is a minimally invasive method for determining drug levels
in human stratum corneum in vivo. It involves repeated application of adhesive tapes on a site
that has been treated with a topical formulation and determination of drug levels in stratum
corneum collected on tape strips.
The dermatopharmacokinetics approach suggested by the Food and Drug Administration
(FDA) proposes to evaluate the level of a topically applied drug in the stratum corneum during
its uptake and clearance so as to calculate classic pharmacokinetic parameters [18]. The
assumption is that stratum corneum concentration-time curves are directly related to concen‐
tration-time curves in the epidermis and dermis.
When applied to diseased skin, topical drug products induce one or more therapeutic
responses, where onset, duration, and magnitude depend on the relative efficiency of three
sequential processes, namely:
• the release of the drug from the dosage form
• penetration of the drug through the skin barrier, and
• generation of the desired pharmacological effect.
Because topical products deliver the drug directly to or near the intended site of action,
measurement of the drug uptake into and drug elimination from the stratum corneum can
provide a dermatopharmacokinetics means of assessing the bioequivalence of two topical drug
products [19,20]. Presumably, two formulations that produce comparable stratum corneum
concentration-time curves may be bioequivalence, just as two oral formulations are judged
Figure 4. Sampling in the skin by microdialysis (http://www.skin-care-forum.basf.com/en/author-articles/strategies-
for-skin-penetration-enhancement/2004/08/12?id=5b9a9164-6148-4d66-bd84-6df76bd6d111&mode=Detail.
Downloaded April 26, 2014)
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bioequivalent if they produce comparable plasma concentration-time curves. Even though the
target site for topical dermatologic drug products in some instances may not be the stratum
corneum, the topical drug must still pass through the stratum corneum, except in instances of
damage, to reach deeper sites of action [21]. In certain instances, the stratum corneum itself is
the site of action. For example, in fungal infections of the skin, fungi reside in the stratum
corneum and therefore dermatopharmacokinetic measurement of an antifungal drug in the
stratum corneum represents direct measurement of drug concentration at the site of action [22].
In instances where the stratum corneum is disrupted or damaged, in vitro drug release may
provide additional information toward the bioequivalent assessment. In this context, the drug
release rate may reflect drug delivery directly to the dermal skin site without passage through
the stratum corneum. For antiacne drug products, target sites are the hair follicles and
sebaceous glands. In this setting, the drug diffuses through the stratum corneum, epidermis,
and dermis to reach the site of action. The drug may also follow follicular pathways to reach
the sites of action. The extent of follicular penetration depends on the particle size of the active
ingredient if it is in the form of a suspension [21, 23-25]. Under these circumstances, the
dermatopharmacokinetic approach is still expected to be applicable because studies indicate
a positive correlation between the stratum corneum and follicular concentrations. Although
the exact mechanism of action for some dermatological drugs is unclear, the dermatopharma‐
cokinetic approach may still be useful as a measure of bioequivalence because it has been
demonstrated that the stratum corneum functions as a reservoir, and stratum corneum
concentration is a predictor of the amount of drug absorbed [26].
For reasons thus cited, dermatopharmacokinetic principles should be generally applicable to
all topical dermatological drug products including antifungal, antiviral, antiacne, antibiotic,
corticosteroid, and vaginally applied drug products. The dermatopharmacokinetic approach
can thus be the primary means to document bioavailability/bioequivalence. Generally,
bioequivalence determinations using dermatopharmacokinetic studies are performed in
healthy subjects because skin where disease is present demonstrates high variability and
changes over time. Use of healthy subjects is consistent with similar use in bioequivalence
studies for oral drug products.
A dermatopharmacokinetic approach is not generally applicable when:
• a single application of the dermatological preparation damages the stratum corneum
• for otic preparations except when the product is intended for otic inflammation of the skin;
and
• for ophthalmic preparations because the cornea is structurally different from the stratum
corneum.
6. Ideal drugs for dermal and transdermal delivery
Owing to the selective nature of the skin barrier, only a small pool of drugs can be delivered
systemically at therapeutically relevant rates [27]. Few drugs constitute the whole segment of
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the transdermal drug market. Besides great potency, the physicochemical drug characteristics
often evoked as favourable for percutaneous delivery include moderate lipophilicity and low
molecular weight [28]. However, a large number of pharmaceutical agents do not fulfill these
criteria. This is especially true for macromolecules, such as insulin, human growth hormone
or cyclosporine, which are very challenging from the drug delivery point of view. The
physicochemical properties of ideal drug for transdermal delivery include:
• Molecular weight less than approximately 1000 Daltons.
• Affinity for both lipophilic and hydrophilic phases. Extreme partitioning characteristics not
ideal.
• Low melting point.
• Should be potent, with short half life and be non-irritating.
Overcoming low skin permeability to xenobiotics can be achieved by a variety of approaches,
and is an active field of research. Their effectiveness and applicability will vary from drug to
drug depending on the physicochemical nature of the compound. New drug discovery is still
a complicated process and generally requires substantial time and monetary investment.
Technologies for formulation change provide the benefit of improving pharmaceutical product
efficacy and safety as well as patient convenience; these technologies provide a relatively
simple approach to creating new pharmaceuticals compared with new drug discovery because
the active compounds used in the formulation have already been approved [29-31]. Nnamani
et al [32] developed and evaluated the antimicrobial activities of an alternative non-invasive,
convenient and cost-effective transdermal drug delivery system (TDDS) containing gentami‐
cin in biodegradable polyester-based matrices. Other drugs which have been formulated for
dermal and transdermal delivery are nitroglycerin, nicotine, scopolamine, clonidine, fentanyl,
17-β-estradiol, testosterone, Boswellic acid (Boswellia serrata) and curcumin (Curcuma longa).
7. Advantages of dermal and transdermal drug delivery
Transdermal delivery provides convenient and pain-free self-administration for patients. It
eliminates frequent dosing administration and plasma level peaks and valleys associated with
oral dosing and injections to maintain constant drug concentrations, and a drug with a short
half-life can be delivered easily. All this leads to enhanced patient compliance, especially when
long-term treatment is required, as in chronic pain treatment and smoking cessation therapy
[3,33,34].
• Avoidance of hepatic first-pass metabolism and the gastrointestinal (GI) tract for poorly
bioavailable drugs is another advantage of transdermal delivery. Elimination of the first-
pass effect allows the amount of drug administered to be lower, and hence, safer in hepato-
compromised patients, resulting in the reduction of adverse effects.
• Transdermal systems are generally inexpensive when compared with other therapies on a
monthly cost basis, as patches are designed to deliver drugs from 1 to 7 days.
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• The other advantage of transdermal delivery is that multiple dosing, on-demand or variable-
rate delivery of drugs is possible with the latest programmable systems, adding more
benefits to the conventional patch dosage forms.
• The general acceptability of transdermal products by patients is very high, which is also
evident from the increasing market for transdermal products.
• Transdermal route permits the use of a relatively potent drug with minimal risk of system
toxicity [35,36].
• In case of toxicity, the transdermal patch can easily be removed by the patient [37].
8. Disadvantages of dermal and transdermal delivery systems
Even though dermal and transdermal delivery systems have a lot of advantages over conven‐
tional topical formulation, it still suffer from a lot of limitations. The disadvantages of dermal
and transdermal delivery systems according to Ranade and Cannon [38] are that:
• Not all drugs are suitable for transdermal delivery.
• Drugs that require high blood levels cannot be administered.
• The adhesive used may not adhere well to all types of skin.
• Drugs or drug formulation may cause sensitization or irritation which must be evaluated
fairly early in the development process.
• The patches may/can be uncomfortable to wear.
• The manufacture requires specialized equipments which results in the formulation being
more expensive to manufacture than conventional dosage forms thus the formulation will
not be economical for most patients.
• There is always a lag time for drug to penetrate through the skin to the systemic circulation,
therefore TDDS is not suitable for drugs requiring rapid onset of action.
• There is a requirement for low dose/high permeable drug. In general a drug with molecular
weight less than 400, logPo/w=2-3 and dose less than 10 mg will be the best candidate for
transdermal delivery.
9. Characterization of dermal and transdermal delivery systems and their
performance
Dermal and transdermal delivery systems are characterized using different methods.
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9.1. Drug solubility determination
The determination of solubility of the drug in the transdermal/dermal matrix early in the
formulation process can avoid crystallization problem, which is one of the instabilities in
transdermal drug delivery systems (TDDS). This instability in the matrix which could be due
to supersaturation makes the formulation metastable and upon storage results in changes in
the liberation/release rate of the drug from the formulation.
9.2. Micromeritic measurements
9.2.1. Particle-size, shape and zeta potential analysis
Light scattering is an important way of characterizing colloidal and macromolecular disper‐
sions and could be useful in assessing properties of particulate TDDS e.g. ethosomes. The
particle size and size distribution are primarily measured using wet laser diffraction sizing
otherwise called dynamic light scattering (DLS) [39]. Size of formulation can also be deter‐
mined using dynamic light scattering (e.g. using a Zetasizer). This is necessary to ascertain the
possible effect of the size on drug release and penetration across barriers in transdermal and
dermal delivery as well as to monitor stability over time. The zeta potential of a formulation
is very important. It is determined using Zetsizer or by other means, and gives information on
the charge of the particles and the tendency of the particles in a formulation to aggregate or to
remain discrete.
9.2.2. Specific surface area
An important parameter of bulk powders is the specific surface area expressed per unit weight.
The specific surface area measurement includes the cracks, crevices, nooks, and crannies
present in the particles. To include these features in the surface-area measurement, methods
have been developed to probe these convoluted surfaces through adsorption by either a gas
or a liquid [40-42]. The most widely used surface area measurement technique is the adsorption
of a monolayer of gas, typically krypton or nitrogen as the adsorbate gas in helium as an inert
diluent, using the method developed by Brunauer, Emmett, and Teller known as the BET
method. Surface area affects spreading and occlusivity of TDDS.
9.3. Visualization by transmission electron microscopy
A combination of transmission electron microscopy (TEM) and freeze fracturing otherwise
referred to as freeze fracture electron microscopy (FFEM) could be used to visualize skin
structures and certain perturbations in the skin. A micrograph image is generated by trans‐
mitting a beam of electrons through a specimen appropriately treated to enhance the visuali‐
zation of skin structural details. High resolution of TEM makes it possible to visualize both
structures and transition processes in the epidermis. Using different techniques, epidermal
granules [43], Langerhans cells [44] and the lipids in stratum corneum and epidermis [45],
amongst others, have been observed. Samples preparation in FFTEM involves freezing the
sample and subsequent longitudinal fracturing approximately parallel to the original skin
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surface under high vacuum [46]. Further treatment could be done on the sample after which
the fracture is viewed under high voltage. This visualization method can provide information
on the interaction between the nanoparticle formulation and the skin. Since the fracture will
always run along the plane of least resistance, FFEM micrographs of treated stratum corneum
often show the lipid coated surfaces of corneocytes or the lipid lamellae.
9.4. Stability
Physical and chemical instabilities of carrier systems often limit their widespread use in
medical applications [47]. Instabilities in ethosomes and other nanocarrier formulations are
caused by hydrolysis or oxidation of the phospholipid molecules and are indicated by leakage
of the encapsulated drug and alterations in vesicle size due to fusion and aggregation [48,49].
Changes in size and size distribution, entrapment efficiency and aggregation of vesicles are
very important parameters in monitoring stability. These parameters can be assessed by EM
or DLS repeatedly over time at varying storage conditions. It has recently been found that
although multilamellar and large unilamellar benzocaine-loaded ethosome vesicles remained
substantially stable with time, in terms of drug entrapment yield and particle dimensions,
small unilamellar vesicles showed high tendency to form aggregates due to increased surface
area exposed to the medium [10]. Such vesicle aggregation indicates instability. In addition,
changes in storage conditions led to marked decrease in particle dimensions and drug-
entrapping yield with less regular morphology for frozen-and-thawed multilamellar etho‐
some dispersions, while the untreated multilamellar and unilamellar vesicular dispersions
remained homogenous and stable with regard to those parameters assessed over the period
[50]. Temperature of formulation and storage conditions affect physical stability of nanopar‐
ticle preparations [10,51].
Optical characteristics, viscosity and physical changes such as cracking or creaming are also
important in assessing stability of ethosomes. Ethosomes are colloidal disperse systems
therefore, cracking and creaming may be observed during storage as in water-in-oil emulsions.
The use of an innovative optical analyzer, Turbiscan Lab® Expert, in studying the influence of
optical characteristics on long-term stability of vesicular colloidal delivery systems has been
advocated [52]. The principle of this measurement is based on the variation of the droplet
volume fraction (migration) or mean size (coalescence), thus resulting in the variation of
backscattering and transmission signals as a function of time. No variation of particle size
occurs when the backscattering profile is within the interval ± 2 %. Variations greater than 10
% either as a positive or negative value in the graphical scale of backscattering are represen‐
tative of an unstable formulation.
9.5. High-pressure liquid chromatography (HPLC)
It is used to monitor the stability of pure drug substance and drugs in formulation with
quantitation of degradation product. A liquid mobile phase is pumped under pressure through
a stainless steel column containing particles of stationary phase with a diameter of 3-10 µm.
The analyte is loaded onto the head of the column via a loop valve and separation of a mixture
occurs according to the relative lengths of time spent by its components in the stationary phase.
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and less dense [150]. The vesicles then squeeze through the intercellular spaces into the deeper
layers of skin. It has been shown that drug particles are concentrated more on the inside wall
than in the core of vesicles [151]. In this position, release of the vesicular content is thermody‐
namically favored. Owing to the increased affinity, due to its lipid content, the vesicle fuses
with the lipid contents of the skin layers and releases its content which then diffuses into deeper
layers of the skin or membrane and into systemic circulation. Other mechanisms, such as the
free drug diffusion, may be involved in penetration.
Figure 8. Mechanism of drug delivery from ethosomal vesicular carriers through the skin [46,115]. Note the initial flu‐
idization of the skin architecture.
12. Regulations on dermal and transdermal delivery systems
Safety and toxicological issues are the most important issues for a drug delivery system. Safety
is an obvious concern for the fast growth of nanoparticles mediated drug delivery [152].
Governmental regulatory agencies such as the United States Food and Drug Agency (USFDA)
have established guidelines describing the kind of safety tests that should be conducted in
animals in order to have a new drug approved for use in clinical trials and in order to get
approval of a new drug application (NDA) for marketing. The rationale and circumstances for
conducting reproductive, mutagenicity, carcinogenicity, irritation, and sensitization studies
have already been mentioned. The requirements for acute, subacute, and chronic toxicity
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studies for pharmaceutical products intended for use in humans as described according to are
the requirements of the United States, Japan, and Europe because these areas represent the
largest pharmaceutical markets in the world today. These requirements have been developed
at the International Conference on Harmonization to provide uniformity among the three
regions [153]. Phases I, II, and III refer to the different phases of human clinical trials. Phase I
refers to the initial trials, limited to one or a few doses to determine absorption, pharmacoki‐
netics, and an initial estimate of safety. Phase II refers to larger scale studies to establish safety
and to get an initial estimate of clinical efficacy. Phase III refers to the final, large-scale,
multicenter trials aimed at establishing efficacy.
The Food and drug agency (FDA) paradigm for regulation of new products is based on the
concepts of risk management, which includes identification, analysis and control of risk [154].
The regulation and approval by the FDA is on a ‘‘product by product’’ basis, with the overall
regulation process falling into three stages: premarket approval, premarket acceptance and
post-market surveillance.
Premarket approval: Prior to market introduction of any new pharmaceuticals, high-risk
medical devices, food additives, colors, and biologicals, FDA approval is required. The
producer/sponsor of the product is responsible for identifying and assessing the risks pre‐
sented by the product. This party will also be responsible for indicating means to minimize
the risks in a product application.
Premarket acceptance: This category refers to products that are often copies of similar products
that were approved previously or are products prepared according to approved specifications.
For these products, the FDA receives and reviews some form of notice that the products will
be marketed and the products undergo a more rapid review process than premarket approval.
Postmarket surveillance: In this category, FDA manages the risks of GRAS products like foods,
cosmetics, radiation emitting electronic products and materials such as food additives and
food packaging. For products in this category, market entry, and distribution are at the
discretion of the manufacturer/producer. These products are generally regulated by the
application of good manufacturing practices. FDA takes regulatory action if adverse events
that threaten public or individual health occur.
The FDA coordinates policies within itself and with other government agencies. As and when
new toxicological risks that derive from the new materials and/or new conformations of
existing materials are identified, the FDA will require new tests.
The FDA regulations are for products, not technologies. In addition, the FDA regulates only
the claims made by the product sponsor. If the manufacturer makes no nanotechnology claims
regarding the manufacture or performance of the product, the FDA may be unaware at the
time that the product under review employed nanotechnology. Finally, the FDA has only
limited authority over some potentially high-risk products, such as cosmetics. Many products
are regulated only if they cause adverse health-related events in use. To date there have been
few resources available to assess the risks of these products.
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13. Dermal and transdermal formulations on the market
A lot of dermal and transdermal drug delivery systems have been licensed for manufacture
after passing through the regulatory approval and trials as specified by different countries
example FDA (United States of America). Some of the drugs currently available on the market
are presented in Table 3.
Drug Trade name Type oftransdermal patch Manufacturer Indication
Fentanyl Duragesic Reservoir Alza/Janssen Pharmaceutica Moderate/ Severe pain
Nitroglycerine Deponit Drug in adhesive Schwarz Pharma Angina Pectoris
Minitran Drug in adhesive 3M Pharmaceuticals
Nitrodisc Micro reservoir Searle, USA
Nitrodur Matrix Key Pharmaceuticals
TransdermNitro Reservoir Alza/Novartis
Nitroderm TTS Face Novartis
Diafusor Matrix Schering-Plough
Transdermal-NTG Rim Warner Chilcott Lab
Nitrocine Rim Kremer Urban
Nitro patch Rim Adria Lab
NTS patch Rim
Bolar, Major, Qualitest, Bio-Line,
Goldline, Geneva, Rugby
WarnerChilcott Lab
Isosorbide dinitrate Frandol Tape Matrix Toaeiyo, Yamanouchi Pharm.
Nicotine Prostep Reservoir ElanCorp/Lederie Labs Smoking Cessation
Nicotrol Drug in adhesive Cygnus Inc./McNeil ConsumerProducts Ltd.
Nicotinell Matrix Novartis
Nikofrenon Matrix Novartis
Habitraol Drug in adhesive Novartis
Testosterone Androderm Reservoir Thera Tech/ GlaxoSmithKline Hypogonadism inmales
Testoderm TTS Reservoir Alza
Clonidine Catapres-TTS Membrane matrixhybrid type Alza/Boehinger Ingelheim Hypertension
Lidocaine Lidoderm Drug in adhesive Cerner Multum, Inc. Anesthetic
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Drug Trade name Type oftransdermal patch Manufacturer Indication
Scopolamine Transderm Scop Membrane matrixhybrid type Alza/Novartis Motion sickness
Hyoscine Trasiderm-Scop Matrix Novartis
Kimite-patch Matrix Myun Moon Pharm. Co.
Minoxidil 4% Nanominox Sinere, Germany Hair growth promoter
Acyclovir Supravir cream Trima, Israel herpes infection.
Many ingredients Cellutight EF Hampden Health, USA Topical cellulite




Vivelle Drug in adhesive Alza/Novartis.
Estraderm Reservoir Women First Healthcare, Inc
Esclim Drug in adhesive Johnson & Johnson
Ethinyl Estradiol Ortho Evra Drug in adhesive
Table 3. Currently available medications for transdermal delivery [155,156].
14. Dermal and transdermal delivery of phytopharmaceuticals
Novel drug delivery system is a novel approach to drug delivery that addresses the limitations
of the traditional drug delivery systems. Phytopharmaceuticals are pharmaceuticals using
traditional compounds derived from botanicals instead of chemicals. Because these natural
ingredients are more easily and more readily metabolized by the body they produce fewer if
any side effects and provide increased absorption in the bloodstream resulting in more
thorough and effective treatments unlike pharmaceuticals produced from chemical com‐
pounds which are prone to adverse side effects [157]. The formulation of dermal and trans‐
dermal delivery of phytopharmaceuticals is gaining interest owing to the benefits accruable
from it. One of the first few attempts to utilize TDDS containing phytopharmaceuticals was
investigation aimed to formulate transdermal films incorporating herbal drug components
such as boswellic acid (Boswellia serrata) and curcumin (Curcuma longa), which utilizes skin as
a site for continuous drug administration into the systemic circulation [157]. TDDS avoids first
pass metabolism of the drug without the pain associated with injection; moreover the system
provides a sustained drug delivery with infrequent dosing via zero-order kinetics and the
therapy can easily be terminated at any time. For the local action of the drug at the site of
administration of TDDS, turmeric are used which is considered a new version of ayuverdic
turmeric poultice or lepa [158].
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Application of vesicular encapsulation holds great promise in the development and use of
phytomedicines considering the difficulties of their formulation into stable dosage forms.
Certain physicochemical properties of many herbal extracts make their formulation difficult
due to stability and processing challenges. By using appropriate techniques, vesicular products
of herbal extracts with enhanced stability and efficacy have been produced. A new drug
delivery device known as phytosome, composed of phosphatidylcholine, has been developed
to overcome the poor absorption of flavonoids, a challenge due mainly to their large molecular
sizes and poor miscibility with the lipid contents of cell membrane linings [159]. Phytosomes
are well absorbed when taken orally.
Evaluations of phytosomes indicate that a bond is formed between a flavonoid and a phos‐
phatidylcholine molecule to form a hybrid that is highly lipid-miscible. The development and
applications of a variety of novel vesicular herbal formulations such as liposomes, phytosomes,
transfersomes and ethosomes have been reported [160,161]. Ethosomes, by virtue of their
special characteristics, may circumvent the hindrances to successful delivery of phytomedi‐
cines. Both soluble and insoluble phytomedines can be encapsulated in ethosomes. Ethosomes
also offer protection from premature degradation and increased biodistribution, which would
make for improved bioavailability and more beneficial therapeutic outcome for TDDS.
15. Conclusion
From the myriad published studies involving nanoparticles,  it  is clear that nanoparticles
have  the  potential  to  effectively  deliver  drugs  across  the  skin  barrier.  Conventional
liposomes, flexible liposomes, ethosomes, niosomes and ultradeformable liposomes, etc offer
potential value as dermal and transdermal drug delivery systems in addition to other lipid
nanoparticles.
Author details
Okoro Uchechi, John D. N. Ogbonna and Anthony A. Attama*
*Address all correspondence to: anthony.attama@unn.edu.ng
Drug Delivery Research Unit, Department of Pharmaceutics, University of Nigeria, Nsukka,
Enugu State, Nigeria
References
[1] Hatto P (2011) ISO concensus definitions relevant to nanomaterials and nanotechnol‐
ogies. 4th Annual Nano Safety for Success Dialogue. ISO TC 229and BSI NTI/1 Nano‐
Nanoparticles for Dermal and Transdermal Drug Delivery
http://dx.doi.org/10.5772/58672
223
technologies Standardization Committees. 29th and 30th March 2011. Brussels.
Available from: http://ec.europa.eu/health/ nanotechnology [Last accessed 15 August
2012].
[2] Devi VK, Saisivam S, Maria GR, Deepti PU (2003) Design and evaluation of matrix
diffusion controlled transdermal patches of verapamil hydrochloride. Drug Dev. Ind.
Pharm. 29:495-503.
[3] Valenta C, Auner BG (2004) The use of polymers for dermal and transdermal deliv‐
ery. Eur. J. Pharm. Biopharm. 58: 279–289.
[4] Block HL (2010) Biopharmaceutics and drug delivery systems In: Comprehensive
Pharmacy Review. Eds. Leon Shargel, Alan H Mutnick, Paul F Souney, Larry N
Swanson, Lippincott Williams and Wilkins, USA. pp. 83-96.
[5] Prausnitz MR, Langer R (2008) Transdermal drug delivery. Nat. Biotech. 26(11):1261–
1268.
[6] Escobar-Chávez JJ, Díaz-Torres R, Rodríguez-Cruz IM, Domínguez-Delgado CL, Mo‐
rales RS, Ángeles-Anguiano E, Melgoza-Contreras LM (2012) Nanocarriers for trans‐
dermal drug delivery. Research and Reports in Transdermal Drug Deliv. 1: 3–17.
[7] Geinoz S, Guy RH, Testa B, Carrupt PA (2004) Quantitative structure–permeation re‐
lationships (QSPeRs) to predict skin permeation: a critical evaluation. Pharm Res.
21:83–92.
[8] Cevc G, Vier IU (2010) Nanotechnology and the transdermal route. A state of the art
review and critical appraisal. J. Control. Rel.141:277–299.
[9] Pinto Reis C, Nuefeld RJ, Ribeiro AJ, et al., (2006) Nanoencapsulation 1. Methods for
preparation of drug-loaded polymeric nanoparticles. Nanomedicine. 2: 8-21.
[10] Maestrelli F, Capasso G, Gonzalez-Rodriguez ML, et al., (2009) Effect of preparation
technique on the properties and in vivo efficacy of benzocaine-loaded ethosomes. J
Liposome Res 19(4): 253-60.
[11] Attama AA, Schicke BC, Paepenmüller T, Müller-Goymann CC (2007) Solid lipid
nanodispersions containing mixed lipid core and a polar heterolipid: Characteriza‐
tion. Eur. J. Pharm. Biopharm. 67: 48-57.
[12] Bernfild M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M (1999)
Functions of cell surface heparan sulphate proteoglycans. Annu. Rev. Biochem. 68:
729-777.
[13] Honary S and Zahir F (2013) Effect of Zeta Potential on the Properties of Nano-Drug
Delivery Systems - A Review (Part 1).Trop. J. Pharm Res. 12 (2): 255-264
[14] Win KY, Feng SS (2005) Effects of particle size and surface coating on cellular uptake
of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26:
2713–2722.
Application of Nanotechnology in Drug Delivery224
[15] Patila S, Sandberg A, Heckert E, Self W, Sea S (2007) Protein adsorption and cellular
uptake of cerium oxide nanoparticles as a function of zeta potential. Biomaterials 28:
4600–4607.
[16] Wolinsky JB, Grinstaff MW (2008) Therapeutic and diagnostic applications of den‐
drimers for cancer treatment. Adv. Drug Deliv. Rev. 60: 1037–1055.
[17] Chang JH, Cho MA, Son HH, Lee CK, Yoon MS, Cho HH, Seo DS, Kim KJ (2006a).
Characterization and formation of phospholipid nanoemulsion coatings on Mg-
modified sericite surface. J. Ind. Eng. Chem, 12: 635-638.
[18] FDA (1998) Guidance for Industry: topical dermatological drug product NDAs and
ANDAs- in vivo bioavailability, bioequivalence, in vitro release and associated studies
(Draft).
[19] Shah, V. P. and H. I. Maibach (eds.), 1993, Topical Drug Bioavailability, Bioequiva‐
lence and Penetration, Plenum Press.
[20] Shah VP, Flynn GL, Yacobi A, et al., (1998) "Bioequivalence of topical dermatological
dosage forms - Methdods of evaluation of bioequivalence," Pharm. Res. 15: 167-171.
[21] Schaefer, H. and T. E. Redelmeir (eds.), 1996, Skin Barrier, Principles of Percutaneous
Absorption, Eds, Karger Publishers.
[22] Pershing LK, Lambert L, Wright ED, et al., (1994) "Topical 0.05% betamethasone di‐
propionate: Pharmacokinetic and pharmacodynamic dose-response studies in hu‐
mans," Arch Dermatol, 130:740-747.
[23] Allec A, Chatelus A, Wagner N (1997) "Skin distribution and pharmaceutical aspects
of adapalene gel," J. Am. Acad. Dermatol. 36: S119-125.
[24] Hueber F, Schaefer H, Wepierre J (1994) Role of transepidermal and transfollicular
routes in percutaneous absorption of steroids: in vitro studies on human skin, Skin
Pharmacology, 7: 237-244.
[25] Illel B, Schaefer H, Wepierre J, Doucet O (1991) Follicles play an important role in
percutaneous absorption, J. Pharm. Sci. 80: 424-427.
[26] Rougier A, Rallis M, Kiren P, Lotte C (1990) "In vivo percutaneous absorption: A key
role for stratum corneum/vehicle partitioning," Arch Dermatol Res. 282: 498-505.
[27] Kalpana SP, Mikolaj M, Courtney LS, Nicole KB, Priyanka G, Audra LS (2010) Chal‐
lenges and opportunities in dermal/transdermal delivery. Ther. Deliv. 1(1): 109–131.
[28] Bos JD, Meinardi MMHM (2000) The 500 Dalton rule for the skin penetration of
chemical compounds and drugs. Ex. Dermatol. 9(3): 165–169.
[29] Tsutomu I, Tohru M (2010) Techniques for efficient entrapment of pharmaceuticals in
biodegradable solid micro/nanoparticle. Expert Opinion Drug Deliv. 7(6): 1-11.
Nanoparticles for Dermal and Transdermal Drug Delivery
http://dx.doi.org/10.5772/58672
225
[30] Moghimi SM, Hunter AC, Murray JC (2005) Nanomedicine: current status and figure
prospects. FASEB J. 19: 311-330.
[31] Marcato PD and Duran N (2008) New aspects of nanopharmaceutical delivery sys‐
tems. J Nanosci Nanotechnology. 6: 2216-2229.
[32] Nnamani PO, Kenechukwu FC, Dibua EU, Ogbonna CC, Momoh MA, Ogbonna
JDN, Okechukwu DC, Olisemeke AU and Attama AA (2013). Bioactivity of gentami‐
cin contained in novel transdermal drug delivery systems (TDDS) formulated with
biodegradable polyesters; Afr. J. Pharm. Pharmacol. 7(28): 1987-1993.
[33] Dnyanesh NT, Vavia PR (2003) Acrylate-based transdermal therapeutic system of ni‐
trendipine. Drug Dev. Ind. Pharm. 29: 71–78.
[34] Chandak AR, Verma PRP (2008) Development and evaluation of HPMC based matri‐
ces for transdermal patches of tramadol. Clin. Res. Reg. Affairs. 25: 13–30.
[35] Mundargi RC, Patil SA, Agnihotri SA, Aminabhavi TM (2007) Evalua-tion and con‐
trolled release characteristics of modified xanthan films for transdermal delivery of
atenolol. Drug Dev. Ind. Pharm. 33:79–90.
[36] Mutalik S, Udupa N (2004) Glibenclamide transdermal patches: Physicochemical,
pharmacodynamic and pharmacokinetic evaluations. J. Pharm. Sci. 93: 1577–1594.
[37] Chang HI, Perrie Y, Coombes AGA (2006) Delivery of the antibiotic gentamicin sul‐
phate from precipitation cast matrices of polycaprolactone. J. Control. Rel.
110:414-421.
[38] Ranade VV, Cannon JB (2011) Drug Delivery Systems, Third Edition, Taylor and
Francis, Boca Raton.
[39] Touitou E, Dayan N, Bergelson L, et al., (2000). Ethosomes-- novel vesicular carriers
for enhanced delivery: characterization and skin penetration properties. J. Control.
Rel. 65: 403-18.
[40] Martin A, Bustamante P (1993) Physical Pharmacy: Physical Chemical Principles in
the Pharmaceutical Sciences, 4th edn, Lippincott Williams & Wilkins, Philadelphia,
PA, pp. 436–439.
[41] Newman A.W (1995) Micromeritics in Physical Characterization of Pharmaceutical
Solids, (ed. H.G. Brittain), Marcel Dekker, New York, NY, Ch. 9, 254–264p.
[42] Chikazawa M, Takei T (1997) Specific Surface Area in Powder Technology Handbook
(eds K. Gotoh, H. Masuda & K. Higashitani), 2nd edn, Marcel Dekker, Inc., New
York, NY, Ch. III. 8, pp. 337–349.
[43] Ishida-Yamamoto A, Simon M, Kishibe M, Miyauchi Y, Takahashi H, Yoshida S,
O'Brien TJ, Serre G, Iizuka H (2004) 'Epidermal lamellar granules transport different
cargoes as distinct aggregates'. Journal of Investigative Dermatology 122(5):
1137-1144.
Application of Nanotechnology in Drug Delivery226
[44] Demarchez M, Asselineau D, Regnier M, Czernielewski J (1992) 'Migration of Lan‐
gerhans Cells into the Epidermis of Human Skin Grafted onto Nude-Mice'. Journal of
Investigative Dermatology, 99(5): S54-S55.
[45] Holman BP, Spies F, Bodde HE (1990) 'An Optimized Freeze-Fracture Replication
Procedure for Human Skin'. Journal of Investigative Dermatology 94(3):332-335.
[46] Norlen L, Al-Amoudi A, Dubochet J (2003) 'A cryotransmission electron microscopy
study of skin barrier formation'. Journal of Investigative Dermatology. 120(4):
555-560.
[47] Stark B, Pabst G, Prassl R (2010) Long-term stability of sterically stabilized liposomes
by freezing and freeze-drying: effects of cryoprotectants on structure. Eur. J. Pharm.
Sci. 41: 546-555.
[48] Lopez-Pinto JM, Gonzalez-Rodriguez ML, Rabasco AM (2005) Effect of cholesterol
and ethanol on dermal delivery from DPPC liposomes. Int. J. Pharm. 298: 1-12.
[49] Nakhla T, Marek M, Kovalcik T (2000) Issues associated with large-scale production
of liposomal formulations. Drug Deliv. Technol. 2:1-6.
[50] Maestrelli F, Gonza´lez-Rodrı´guez ML, Rabasco AM, et al., (2006). Effect of prepara‐
tion technique on the properties of liposomes encapsulating ketoprofen-cyclodextrin
complexes aimed for transdermal delivery. Int. J. Pharm. 312:53-60.
[51] Attama AA, Müller-Goymann CC (2008) Effect of beeswax modification on the lipid
matrix and solid lipid nanoparticle crystallinity. Colloids and Surfaces A: Physico‐
chemical and Engineering Aspects. 315: 189-195.
[52] Celia C, Trapasso E, Cosco D, et al (2009) Turbiscan Lab® Expert analysis of the sta‐
bility of ethosomes and ultradeformable liposomes containing a bilayer fluidizing
agent. Colloids Surf B Biointerfaces 72: 155-60.
[53] Watson DG (1999) Pharmaceutical Analysis. A textbook for Pharmaceutical students
and Pharmaceutical Chemists. 1st Ed. Churchil Livingstone, UK.
[54] Coderch L, de Pera M, Perez-Cullell N, Estelrich J, de la Maza A, Parra JL (1999) 'The
effect of liposomes on skin barrier structure'. Skin Pharmacol. Applied Skin Physiol.,
12(5): 235-246.
[55] Curdy C, Naik A, Kalia YN, Alberti I, Guy RH (2004) 'Non-invasive assessment of
the effect of formulation excipients on stratum corneum barrier function in vivo'. Int.
J. Pharm. 271(1-2): 251-256.
[56] Honeywell-Nguyen PL, Gooris GS, Bouwstra JA (2004) 'Quantitative assessment of
the transport of elastic and rigid vesicle components and a model drug from these
vesicle formulations into human skin in vivo'. J. Investig. Dermatol. 123(5): 902-910.
Nanoparticles for Dermal and Transdermal Drug Delivery
http://dx.doi.org/10.5772/58672
227
[57] Jadoul A, Doucet J, Durand D, Preat V (1996) 'Modifications induced on stratum cor‐
neum structure after in vitro iontophoresis: ATR-FTIR and X-ray scattering studies'. J.
Control. Rel. 42(2):165-173.
[58] Attama AA, Müller-Goymann CC (2006) A critical study of novel physically struc‐
tured lipid matrices composed of a homolipid from Capra hircus and theobroma oil.
Int. J. Pharm. 322, 67-78.
[59] Brinkmann I, Müller-Goymann CC (2005) An attempt to clarify the influence of glyc‐
erol, propylene glycol, isopropyl myristate and a combination of propylene glycol
and isopropyl myristate on human stratum corneum. Pharmazie. 60: 215-220.
[60] Oilman MR (1982). Skin and Eye Testing in Animals. Principles and Methods of Toxi‐
cology; Hayes, A.W., Ed.; Raven Press: New York. 209–222p.
[61] Garg A, Aggarwal D, Garg S, Singla AK (2002). Spreading of Semisolid Formulations
An Update. Pharmaceutical Technology, Sept.
[62] Idson B, Lazarus J.J (1987) Semisolids. In The Theory and Practice of Industrial Phar‐
macy, L. Lachman, H.A. Lieberman, and J.L. Kanigs, Eds. Lea and Febiger, Philadel‐
phia, PA, 2d ed. pp. 215–244.
[63] Duggin G (1996) Softening skin with emollient ingredients. Manufacturing Chemist
67 (6): 27–31.
[64] Barry BW, Grace AJ (1972) Sensory testing of spreadability: Investigation of rheologi‐
cal conditions operative during application of topical preparations,” J. Pharm. Sci.
61(3): 335–341.
[65] Rance RW (1973) Studies of the factors controlling the action of hair sprays. Part I:
The spreading of hair spray resin solutions on hair. J. Soc. Cosm. Chem. 24 (7): 501–
522.
[66] Islam MT, Rodríguez-Hornedo N, Ciotti S, Ackermann C (2004) Rheological charac‐
terization of topical Carbomer gels neutralized to different pH. Pharm. Res. 21(7):
1192-1199.
[67] Lawrence MJ, Rees GD (2000) Microemulsion-based media as novel drug delivery
systems. Adv Drug Deliv Rev. 45: 89-121.
[68] Kreilgaard M (2002) Influence of microemulsions on cutaneous drug delivery. Adv
Drug Deliv Rev. 54: S77-S98.
[69] He W, Tan Y, Tian Z, et al., (2011). Food protein-stabilized nanoemulsions as poten‐
tial delivery systems for poorly water-soluble drugs: preparation, in vitro characteri‐
zation and pharmacokinetics in rats. Int J Nanomedicine. 6: 521-533.
[70] Heuschkel S, Goebel A, Neubert RHH (2008) Microemulsions —modern colloidal
carrier for dermal and transdermal drug delivery. J Pharm Sci. 97: 603-631.
Application of Nanotechnology in Drug Delivery228
[71] Zhao X, Liu J, Zhang X, et al., (2006) Enhancement of transdermal delivery of theo‐
phylline using microemulsion vehicle. Int. J. Pharm. 327: 58-64.
[72] Neubert RHH (2011) Potentials of new nanocarriers for dermal and transdermal
drug delivery. Eur J Pharm Biopharm. 77: 1-2.
[73] Grampurohit N, Ravikumar P, Mallya R (2011) Microemulsions for topical use–a re‐
view. Ind J Pharm Edu Res. 45: 100-107.
[74] Valenta C, Schultz K (2004) Influence of carrageenan on the rheology and skin per‐
meation of microemulsion formulations. J. Control. Rel. 95: 257-265.
[75] Sonneville-Aubrun O., Simonnet J.T., L’Alloret F (2004) Nanoemulsions: a new vehi‐
cle for skincare products. Adv Colloid Interface Sci. 108–109:145–149.
[76] Seiden MV, Muggia F, Astrow A, et al (2004) A phase II study of liposomal lurtotecan
(OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol Oncol. 93: 229–
232.
[77] Kuo F, Subramanian B, Kotyla T, Wilson TA, Yoganathan S, Nicolosi RJ (2008) Nano‐
emulsions of an anti-oxidant synergy formulation containing gamma tocopherol
have enhanced bioavailability and anti-inflammatory properties. Int. J. Pharm.
363:206–213.
[78] Wu H, Ramachandran C, Bielinska AU, et al (2001) Topical transfection using plas‐
mid DNA in a water-in-oil nanoemulsion. Int. J. Pharm. 221:23–34.
[79] Subramanian B, Kuo F, Ada E, et al (2008) Enhancement of anti-inflammatory prop‐
erty of aspirin in mice by a nano-emulsion preparation. Int. Immunopharmacol.
2008;8:1533–1539.
[80] Mou D, Chen H, Du D, et al (2008) Hydrogel-thickened nanoemulsion system for
topical delivery of lipophilic drugs. Int. J. Pharm. 353: 270–276.
[81] Wu H, Ramachandran C, Weiner ND, Roessler BJ (2001) Topical transport of hydro‐
philic compounds using water-in-oil nanoemulsions. Int. J. Pharm. 220: 63–75.
[82] Alves MP, Scarrone AL, Santos M, Pohlmann AR, Guterres SS (2007) Human skin
penetration and distribution of nimesulide from hydrophilic gels containing nano‐
carriers. Int. J. Pharm. 341: 215–220.
[83] Kumar VS, Asha K (2011) Herbosome a Novel carrier for herbal drug delivery. Int. J
Current Pharm. Res. 3(3): 36-41.
[84] Jung S, Otberg N, Thiede G, Richter H, Sterry W, Panzner S, Lademann J (2006) Inno‐
vative liposomes as a transfollicular drug delivery system: penetration into porcine
hair follicles. J. Invest. Dermatol. 126: 1728–1732.
Nanoparticles for Dermal and Transdermal Drug Delivery
http://dx.doi.org/10.5772/58672
229
[85] Honeywell-Nguyen PL, Wouter Groenink HW, de Graaff AM, Bouwstra JA (2003)
The in vivo transport of elastic vesicles into human skin: effects of occlusion, volume
and duration of application. J Control. Rel. 90: 243–255.
[86] Honeywell-Nguyen PL, de Graaff AM, Groenink HW, Bouwstra JA (2002) The in
vivo and in vitro interactions of elastic and rigid vesicles with human skin. Biochim.
Biophys. Acta. 1573: 130–140.
[87] Verma DD, Verma S, Blume G, Fahr A (2003) Liposomes increase skin penetration of
entrapped and non-entrapped hydrophilic substances into human skin: a skin pene‐
tration and confocal laser scanning microscopy study. Eur. J. Pharm. Biopharm. 55:
271–277.
[88] Cui Z, Han S, Padinjarae D, Huang L (2005) Immunostimulation mechanism of LPD
nanoparticles as a vaccine carrier. Mol. Pharm. 2: 22–28.
[89] Herffernan M, Murthy N (2005) Polyketal nanoparticles: a new pH-sensitive biode‐
gradable drug delivery vehicle. Bioconjug. Chem. 16: 1340–1342.
[90] Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK (2007) Dermal and trans‐
dermal delivery of an anti-psoriatic agent via ethanolic liposomes. J. Control. Rel.
123: 148–154.
[91] Manosroi A, Kongkaneramit L, Manosroi J (2004) Stability and transdermal absorp‐
tion of topical amphotericin B liposome formulations. Int. J. Pharm. 270: 279–286.
[92] Maestrelli F, González-Rodríguez ML, Rabasco AM, Mura P (2005) Preparation and
characterisation of liposomes encapsulating ketoprofen–cyclodextrin complexes for
transdermal drug delivery. Int. J. Pharm. 298: 55–67.
[93] Essa EA, Bonner MC, Barry BW (2004) Electrically assisted skin delivery of liposomal
estradiol; phospholipid as damage retardant. J. Control. Rel. 95: 535–546.
[94] Sharma BB, Jain SK, Vyas SP (1994) Topical liposome system bearing local anaesthet‐
ic lignocaine: preparation and evaluation. J. Microencapsul. 11: 279–286.
[95] Uchegbu IF, Florence AT (1995) Non-ionic surfactant vesicles (niosomes): physical
and pharmaceutical chemistry. Adv. Colloid Interface Sci. 58: 1-55.
[96] Vora B, Khopade AJ, Jain NK (1998) Proniosome based transdermal delivery of levo‐
norgestrel for effective contraception. J. Control. Rel. 54: 149-165.
[97] Alsarra IA, Bosela AA, Ahmed SM, Mahrous GM (2005) Proniosomes as a drug carri‐
er for transdermal delivery of ketorolac. Eur. J. Pharm. Biopharm. 59: 485–490.
[98] Muzzalupo R, Tavano L, Cassano R, Trombino S, Ferrarelli T, Picci N (2011) A new
approach for the evaluation of niosomes as effective transdermal drug delivery sys‐
tems. Eur. J. Pharm. Biopharm. 79: 28–35.
Application of Nanotechnology in Drug Delivery230
[99] Manconi M, Caddeo C, Sinico C, et al (2011) Ex vivo skin delivery of diclofenac by
transcutol containing liposomes and suggested mechanism of vesicle–skin interac‐
tion. Eur. J. Pharm. Biopharm. 78: 27–35.
[100] Mura S, Manconi M, Sinico C, Valenti D, Fadda AM (2009) Penetration enhancer con‐
taining vesicles (PEVs) as carriers for cutaneous delivery of minoxidil. Int. J. Pharm.
380: 72–79.
[101] Guinedi AS, Mortada ND, Mansour S, Hathout RM (2005). Preparation and evalua‐
tion of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers
of acetazolamide. Int. J. Pharm. 306: 71–82.
[102] Balakrishnana P, Shanmugama S, Lee WS, et al (2009) Formulation and in vitro as‐
sessment of minoxidil niosomes for enhanced skin delivery. Int. J. Pharm. 377: 1–8.
[103] Junyaprasert VB, Singhsa P, Suksiriworapong J, Chantasart D (2012) Physicochemical
properties and skin permeation of Span 60/Tween 60 niosomes of ellagic acid. Int. J.
Pharm. 423: 303–311.
[104] Jain S, Jain P, Umamaheshwari RB, Jain NK (2003) Transfersomes—A Novel Vesicu‐
lar Carrier for Enhanced Transdermal Delivery: Development, Characterization, and
Performance Evaluation. Drug Dev. Ind. Pharm. 29 (9): 1013-1026.
[105] Planas ME, Gonzalez P, Rodriguez S, Sanchez G, Cevc G (1992) Non-invasive percu‐
taneous induction of topical analgesia by a new type of drug carrier and prolonga‐
tion of the local pain intensity by liposomes. Anesth. Analge. 95: 615–621.
[106] Cevc G, Schatzlein A, Blume G (1995) Transdermal drug carrier basic properties, op‐
timization and transfer efficiency in the case of epicutaneously applied peptides. J.
Control. Rel. 36: 3–16.
[107] Paul A, Cevc G, Bachhawat BK (1998). Transdermal immunization with an integral
membrane component gap junction protein, by means of ultradeformable drug carri‐
ers, transfersomes. Vaccine 16: 188–195.
[108] Mbah CC, Builders PF, Attama AA (2014). Nanovesicular carriers as alternative drug
delivery systems: ethosomes in focus Expert Opin. Drug Deliv. 11(1):1-15.
[109] Touitou E (1996). Composition of applying active substances to or through the skin.
US5716638.
[110] Jain S, Tiwary AK, Sapra B, Jain NK (2007). Formulaion and evaluation of thosomes
for transdermal delivery of lamivudine. AAPS PharmSciTech. 8(4): Article 111.
[111] Coderch L., Fonollosa J., De Pera M., et al (2000) Influence of cholesterol on liposome
fluidity by EPR: relationship with percutaneous absorption. J Control. Rel. 68: 85-95.
[112] Serikawa T, Kikuchi A, Sugaya S, et al., (2006) In vitro and in vivo evaluation of novel
cationic liposomes utilized for cancer gene therapy. J. Control. Rel. 113(3): 255-260.
Nanoparticles for Dermal and Transdermal Drug Delivery
http://dx.doi.org/10.5772/58672
231
[113] Barry BW (2004) Breaching the skin’ barrier to drugs. Nat. Biotechnol. 22: 165-167.
[114] Honeywell-Nguyen PL, Bouwstra JA (2005) Vesicles as a tool for transdermal and
dermal delivery. Drug Discov. Today. 2: 67-74.
[115] Elsayed MMA, Abdallah OY, Naggar VF, et al., (2007a). Lipid vesicles for skin deliv‐
ery of drugs: reviewing three decades of research. Int. J. Pharm. 332: 1-16.
[116] Ainbinder D, Touitou E (2005) Testosterone ethosomes for enhanced transdermal de‐
livery. Drug Deliv. 12: 297-303.
[117] Paolino D, Lucania G, Mardente D, et al., (2005) Ethosomes for skin delivery of am‐
monium glycyrrhizinate: in vitro percutaneous permeation through human skin and
in vivo anti-inflammatory activity on human volunteers. J. Control. Rel. 106: 99-110.
[118] Dayan N, Touitou E (2000) Carriers for skin delivery of trihexyphenidyl HCl: etho‐
somes vs. liposomes. Biomaterials. 21: 1879-85.
[119] Elsayed MM, Abdallah OY, Naggar VF, et al., (2007b) Deformable liposomes and
ethosomes as carriers for skin delivery of ketotifen. Pharmazie 62: 133-137
[120] Li G, Fan Y, Fan C, et al. (2012) Tacrolimus-loaded ethosomes: physicochemical char‐
acterization and in vivo evaluation. Eur. J. Pharm. Biopharm. In press 2012.
[121] Chourasia MK, Kang L, Chan SY (2011) Nanosized ethosomes bearing ketoprofen for
improved transdermal delivery. Results Pharm Sci. 1: 60–67.
[122] Fang YP, Huang YB, Wua PC, Tsai YH (2009) Topical delivery of 5-aminolevulinic
acid-encapsulated ethosomes in a hyperproliferative skin animal model using the
CLSM technique to evaluate the penetration behavior. Eur J Pharm Biopharm. 73:
391–398.
[123] Paolino D, Lucania G, Mardente D, Alhaique F, Fresta M (2005) Ethosomes for skin
delivery of ammonium glycyrrhizinate: in vitro percutaneous permeation through
human skin and in vivo anti-inflammatory activity on human volunteers. J Control.
Rel. 106: 99–110.
[124] Touitou E, Dayan N, Bergelson L, Godina B, Eliaz M (2000) Ethosomes – novel vesic‐
ular carriers for enhanced delivery: characterization and skin penetration properties.
J Control. Rel. 65: 403–418.
[125] Maheshwari RGS, Tekade RK, Sharma PA, et al (2012) Ethosomes and ultradeforma‐
ble liposomes for transdermal delivery of clotrimazole: a comparative assessment.
Saudi Pharm J. 20: 161–170.
[126] Dayan N, Touitou E (2000) Carriers for skin delivery of trihexyphenidyl HCl: etho‐
somes vs liposomes. Biomaterials. 21: 1879–1885.
[127] Parekh HS (2007) The advance of dendrimers– a versatile targeting platform for
gene/drug delivery. Curr. Pharm Des. 13, 2837–2850.
Application of Nanotechnology in Drug Delivery232
[128] Esfand R, Tomalia DA (2001) Poly(amidoamine) (PAMAM) dendrimer: from biomi‐
micry to drug delivery and biomedical applications. Drug Discov. Today 6:427–436.
[129] D’Emanuele A, Attwood D (2005) Dendrimer-drug interactions. Adv. Drug Deliv.
Rev. 57: 2147–2162.
[130] Wang Z, Itoh Z, Hosaka Y, et al (2003) Novel transdermal drug delivery system with
polyhydroxyalkanoate and starburst polyamidoamine dendrimer. J Biosci Bioeng. 95:
541–543.
[131] Chauhan AS, Sridevi S, Chalasani KB, et al (2003) Dendrimer-mediated transdermal
delivery: enhanced bioavailability of indomethacin. J. Control. Rel. 90: 335–343.
[132] Yiyun C, Na M, Tongwen X, et al (2007). Transdermal delivery of nonsteroidal anti-
inflammatory drugs mediated by polyamidoamine (PAMAM) dendrimer. J. Pharm.
Sci. 96: 595–602.
[133] Venuganti VVK, Perumal OP (2008) Effect of poly(amidoamine) (PAMAM) dendrim‐
er on skin permeation of 5-fluorouracil. Int. J. Pharm. 361: 230–238.
[134] Niederhafner P, Šebestík J, Ježek J (2005) Peptide dendrimers. J. Peptide Sci. 11: 757–
788.
[135] Mehnert W, Mäder K (2001) Solid lipid nanoparticles. Production, characterization
and applications. Adv Drug Del Rev. 47: 165–96.
[136] Müller RH, Keck CM (2004) Challenges and solutions for the delivery of biotech
drugs – a review of drug nanocrystal technology and lipid nanoparticles. J Biotech.
113: 151–70.
[137] Castelli F, Puglia C, Sarpietro MG, et al (2005) Characterization of indomethacin-
loaded lipid nanoparticles by differential scanning calorimetry. Int. J. Pharm. 304:
231–238.
[138] Siekmann B, Westesen K (1992) Submicron-sized parenteral carrier systems based on
solid lipids. Pharm. Pharmacol. Lett. 1: 123–126.
[139] Manjunath K, Venkateswarlu V (2005) Pharmacokinetics, tissue distribution and bio‐
availability of clozapine solid lipid nanoparticles after intravenous and intraduode‐
nal administration. J. Control. Rel. 107: 215–28.
[140] Müller RH, Souto EB, Radtke M (2000) PCT application PCT/EP00/04111.
[141] Attama AA, Momoh MA and Builders PF. Lipid Nanoparticulate Drug Delivery Sys‐
tems: A Revolution in Dosage Form Design and Development. InTech. 2012:1-34.
http://www.intechopen.com/subjects/pharmacology-toxicology-and-pharmaceutical-
science.
[142] Wissing SA, Müller RH (2002) The influence of the crystallinity of lipid nanoparticles
on their occlusive properties. Int. J. Pharm. 242(1-2): 377-379.
Nanoparticles for Dermal and Transdermal Drug Delivery
http://dx.doi.org/10.5772/58672
233
[143] Jenning V, Thünemann AF, Gohla SH (2000) Characterisation of a Novel Solid Lipid
Nanoparticle Carrier System Based on Binary Mixtures of Liquid and Solid Lipids.
Int. J. Pharm. 199(2): 167–177.
[144] Villalobos-Hernandez JR, Müller-Goymann CC (2006) Sun protection enhancement
of titanium dioxide crystals by the use of carnauba wax nanoparticles: The synergis‐
tic interaction between organic and inorganic sunscreens at nanoscale. Int. J. Pharm.
322(1-2): 161-170.
[145] Guterres SS, Alves MP and Adriana R (2007) Pohlmann.Polymeric nanoparticles,
nanospheres and nanocapsules, for cutaneous application. Drug Target Insights. 2:
147–157.
[146] Xu ZP (2006) Inorganic nanoparticles as carriers for efficient cellular delivery. Chem.
Eng. Sci. 61: 1027–40.
[147] Scheindlin S (2004) Transdermal drug delivery: past, present, future. Mol. Interv.
4(6): 308–312.
[148] Micromedex 1.0 (Healthcare Series) Thomson Reuters. [Accessed 27 December, 2013].
www.thomsonhc.com/home.
[149] Yarosh DB (1992) Liposome-encapsulated enzymes for DNA repair. In: Braun-Falco
O, Korting HC, Maibach H, editors. Liposome dermatics. Springer-Verlag; Heidel‐
berg. pp. 258-69.
[150] Barry BW (2001) Novel mechanisms and devices to enable successful transdermal
drug delivery. Eur. J. Pharm. Sci. 14(2):101-14
[151] Al-Obaidi H, Nasseri B, Florence AT (2010) Dynamics of lipid microparticles inside
lipid vesicles: movement in confined spaces. J. Drug Target. 18(10): 821-830.
[152] Chiranjib C, Souman P, George PDC, Zhi-Hong W, Chan-Shing L (2013) Nanoparti‐
cle as smart pharmaceutical delivery. Frontiers in Bioscience (Landmark Ed) 18:
1030-1050.
[153] International Conference on Harmonisation Guidance on Nonclinical Safety Studies
for the Conduct of Human Clinical Trials for Pharmaceuticals. Federal Register 1997;
62 (227): 62922–62925.
[154] Makena H and Uday B. Kompella (2006) Nanotechnology and Nanoparticles: Clini‐
cal, Ethical, and Regulatory Issues. In Nanoparticle nanotechnology for drug deliv‐
ery. vol. 159. Ed by Ram B Gupta AND Uday Kompella. pp. 381-393.
[155] Florence AT, Attwood D (2009) Physicochemical principles of Pharmacy. 4th Ed.
Pharmaceutical Press, UK. 329-390p.
[156] Wertz PW, Miethke MC, Long SA, Strauss JS, Downing DT (1985) The composition
of ceramides from human stratum corneum and from comedones.Journal of Investi‐
gative Dermatology 84: 410–12.
Application of Nanotechnology in Drug Delivery234
[157] Devi VK, Nimisha J, Valli SK (2010) The importance of novel drug delivery systems
in herbal medicines. Pharmacognosy Review. 4(7): 27-31.
[158] Verma M, Gupta PK, Varsha BP, Purohit AP (2007) Development of transdermal
drug dosage formulation for the anti-rheumatic ayurvedic medicinal plants. Ancient
Sci. Life. 11: 66-69.
[159] Kidd PM (2011) Phytosome: A technical revolution in phytomedicine. Available
from: www.indena.com [Last accessed 10 September 2011].
[160] Ajazuddin SS (2010) Applications of novel drug delivery system for herbal formula‐
tions. Fitoterapia. 81: 680-9.
[161] Goyal A, Kumar S, Nagpal M, et al., (2011) Potential of novel drug delivery systems
for herbal drugs. Ind. J. Pharm. Edu. Res. 45(3): 225-235.
Nanoparticles for Dermal and Transdermal Drug Delivery
http://dx.doi.org/10.5772/58672
235

